JAESCHKE, GEORG,LINDEMANN, LOTHAR,WICHMANN, JUERGEN,VIEIRA, ERIC
申请号：
PE0000352012
公开号：
PE03972012A1
申请日:
2010.07.14
申请国别(地区):
PE
年份:
2012
代理人:
摘要：
Referring to an imidazole Derivative of formula (i), wherein R1 is Halogen, alkyl or alkoxy C1 - C6 C1 - C6 alkyl R2 is C1 - C6, hidroxialquilo c1-c6 alkyl or alkoxy C1 - C6 C1 - C6 R3 is C1 - C6 h, alkyl or alkoxy, hidroxialquilo C1 - C6 C1 - C6 C1 - C6 alkyl R4 q is n or CH, is a group of formula (ii) or (ii) (b) X, y and Z is n or CH, R5 and R6 are h, alkyl of C1 - C6 C1 - C6 alkoxyalkyl esters, hidroxialquilo C1 - C6Among others. Preferred compounds are: 4 - [4 - (3 - Chloro - feniletinil) - 2-methyl - imidazol-1-yl] - 1 - (2 - hydroxy ethyl) - 1H - pyridin - One - 2, 4 - [4 - (2 - chlorine - pyridin - 4 - iletinil) - 2 Methyl imidazol-1-yl] - 1H - pyridin - One - 2, 4 - [4 - (3 - Chloro - feniletinil) - 2-methyl - imidazol-1-yl] - 1H - pyridin - One - 2, 4 - [4 - (3 - Chloro - feniletinil) - 2 imidazo - Methyl L - 1 - yl] - 1 - methyl - 2 - 1H - pyridin - ona, among others.It also relates to a Pharmaceutical composition. These compounds are antagonists of metabotropic glutamate receptor 5 (mGluR5) and are useful in the treatment of Alzheimers disease, Parkinsons disease, Schizophrenia, among othersREFERIDA A UN DERIVADO DE IMIDAZOL DE FORMULA (I), DONDE R1 ES HALOGENO, ALQUILO C1-C6 O ALCOXI C1-C6 R2 ES ALQUILO C1-C6, HIDROXIALQUILO C1-C6 O ALCOXI C1-C6-ALQUILO C1-C6 R3 ES H, ALQUILO C1-C6, HIDROXIALQUILO C1-C6 O ALCOXI C1-C6-ALQUILO C1-C6 Q ES N O CH R4 ES UNGRUPO DE FORMULA (IIa) O (IIb) X, Y Y Z SON CH O N R5 Y R6 SON H, ALQUILO C1-C6, ALCOXIALQUILO C1-C6, HIDROXIALQUILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-[4-(3-CLORO-FENILETINIL)-2-METIL-IMIDAZOL-1-IL]-1-(2-HIDROXI-ETIL)-1H-PIRIDIN-2-ONA, 4-[4-(2-CLORO-PIRIDIN-4-ILETINIL)-2-METIL-IMIDAZOL-1-IL]-1H-PIRIDIN-2-ONA, 4-[4-(3-CLORO-FENILETINIL)-2-METIL-IMIDAZOL-1-IL]-1H-PIRIDIN-2-ONA, 4-[4-(3-CLORO-FENILETINIL)-2-METIL-IMIDAZOL-1-IL]-1-METIL-1H-PIRIDIN-2-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES METABOTROPICOS DE GLUTA
